Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 216 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | active not recruiting | Phase 2 | 66 | Meghan SheaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06536517 | The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | recruiting | Phase 2 | 100 | Johns Hopkins UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06562166 | Online Adaptive Radiotherapy for Cervical Cancer | recruiting | Phase 2 | 124 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 120 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06463028 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | recruiting | Phase 2 | 40 | Faeth TherapeuticsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07167160 | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial | recruiting | Phase 2 | 59 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07232654 | Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07244965 | Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05997017 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | recruiting | Phase 2 | 29 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | recruiting | Phase 2 | 60 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib(DURAFAK) | recruiting | Phase 2 | 55 | University of OklahomaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05990803 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | recruiting | Phase 2 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | not yet recruiting | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer(RODEO) | not yet recruiting | Phase 2 | 40 | University College, LondonOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07130240 | Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104149 | Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07092696 | Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer | recruiting | Phase 2 | 34 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06942377 | Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy | not yet recruiting | Phase 2 | 140 | Peking University People's HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07003620 | Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial | recruiting | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium(WE-FiERCE) | not yet recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 0 | Jun 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 14, 2026source: clinicaltrials